- Home
- EVC vs SKYE Comparison
EVC vs SKYE Comparison
Compare EVC & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVC
- SKYE
- Stock Information
- Founded
- EVC 1996
- SKYE 2012
- Country
- EVC United States
- SKYE United States
- Employees
- EVC N/A
- SKYE N/A
- Industry
- EVC Broadcasting
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- EVC Industrials
- SKYE Health Care
- Exchange
- EVC Nasdaq
- SKYE Nasdaq
- Market Cap
- EVC 166.9M
- SKYE 172.9M
- IPO Year
- EVC 2000
- SKYE N/A
- Fundamental
- Price
- EVC $1.97
- SKYE $6.35
- Analyst Decision
- EVC Hold
- SKYE Strong Buy
- Analyst Count
- EVC 1
- SKYE 5
- Target Price
- EVC $1.75
- SKYE $18.40
- AVG Volume (30 Days)
- EVC 270.1K
- SKYE 142.7K
- Earning Date
- EVC 10-31-2024
- SKYE 08-09-2024
- Dividend Yield
- EVC 10.23%
- SKYE N/A
- EPS Growth
- EVC N/A
- SKYE N/A
- EPS
- EVC N/A
- SKYE N/A
- Revenue
- EVC $1,126,331,000.00
- SKYE N/A
- Revenue This Year
- EVC N/A
- SKYE N/A
- Revenue Next Year
- EVC N/A
- SKYE N/A
- P/E Ratio
- EVC N/A
- SKYE N/A
- Revenue Growth
- EVC 65.95
- SKYE N/A
- 52 Week Low
- EVC $1.33
- SKYE $1.44
- 52 Week High
- EVC $4.41
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- EVC 49.95
- SKYE 53.72
- Support Level
- EVC $1.89
- SKYE $5.71
- Resistance Level
- EVC $2.08
- SKYE $6.69
- Average True Range (ATR)
- EVC 0.09
- SKYE 0.73
- MACD
- EVC -0.00
- SKYE 0.12
- Stochastic Oscillator
- EVC 34.11
- SKYE 57.33
About EVC Entravision Communications Corporation
Entravision Communications Corp is a global advertising solutions, media, and technology company. Its operations encompass integrated marketing and media solutions, comprised of television, radio, and digital properties and data analytics services. The company operates in television broadcasting, audio broadcasting, and digital media segments. The Company's digital segment, whose operations are located in Europe, Latin America, Asia, the United States, and Africa. The Company's television and audio operations reach and engage U.S. Hispanics in the United States.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.